Company: VVR
Filing Date: 2025-03-21
Form Type: 424B5
Source: 0001104659-25-026711
Chunk: 162

Company: Invesco Senior Income Trust
Filing Date: 2025-03-21
Form: 424B5
Chunk 162
---
 opportunity to review and understand what issues may be raised. Related-party transactions: Invesco will vote all related party transactions on a case-by-case basis. The vote analysis will consider the following factors, among others: ● disclosure of the transaction details must be full and transparent (such as details of the related parties and of the transaction subject, timeframe, pricing, potential conflicts of interest, and other terms and conditions); ● the transaction must be fair and appropriate, with a sound strategic rationale; ● the company should provide an independent opinion either from the supervisory board or an external financial adviser; ● minority shareholders’ interests should be protected; and ● the transactions should be on an arm’s length basis. Routine business items and formalities: Invesco generally votes non-contentious routine business items and formalities as recommended by the issuer’s management and board of directors. Routine business items and formalities generally include proposals to: ● accept or approve a variety of routine reports; and ● approve provisionary financial budgets and strategy for the current year. B. Accountability Robust shareholder rights and strong board oversight help ensure that management adhere to the highest standards of ethical conduct, are held to account for poor performance and responsibly deliver value creation for stakeholders over the long term. We encourage companies to adopt governance B-11 features that ensure board and management accountability. In particular, we consider the following as key mechanisms for enhancing accountability to investors: One share one vote: Voting rights are an important tool for investors to hold boards and management teams accountable. Unequal voting rights may limit the ability of investors to exercise their stewardship obligations. ● We generally do not support proposals that establish or perpetuate dual classes of voting shares, double voting rights or other means of differentiated voting or disproportionate board nomination rights. ● We generally support proposals to decommission differentiated voting rights. ● Where unequal voting rights are established, we expect these to be accompanied by reasonable safeguards to protect minority shareholders’ interests. Anti-takeover devices: Mechanisms designed to prevent or delay takeover attempts may unduly limit the accountability of boards and management teams to shareholders. ● We generally will not support proposals to adopt antitakeover devices such as poison pills. Exceptions may be warranted at entities without significant operations and to preserve the value of net operating losses carried forward or where the applicability of the pill is limited in scope and duration. ● In addition, we will generally not support capital authorizations or amendments to corporate articles or bylaws at operating companies that may be utilized for antitakeover purposes, for example, the